Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study

Dana V. Rizk,Brad H. Rovin,Hong Zhang,Naoki Kashihara,Bart Maes,Hernán Trimarchi,Vlado Perkovic,Matthias Meier,Dmitrij Kollins,Olympia Papachristofi,Alan Charney,Jonathan Barratt

Kidney International Reports（2023）

引用 4|浏览23

暂无评分

摘要

APPLAUSE-IgAN will evaluate the benefits and safety of iptacopan, a novel targeted therapy for IgAN, in reducing complement-mediated kidney damage and thus slowing or preventing disease progression.

查看译文

关键词

alternative complement pathway, eGFR slope, Factor B, IgAN, iptacopan (LNP023), proteinuria

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要